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Duesseldorf and Rostock, Germany
Intracoronary and intramyocardial stem cell therapy aim at the repair of compromised myocardium thereby—
as a causal treatment—preventing ventricular remodeling and improving overall performance. Since the first-in-
human use of bone marrow stem cells (BMCs) after acute myocardial infarction in 2001, a large number of clini-
cal studies have demonstrated their clinical benefit: BMC therapy can be performed with usual cardiac catheter-
ization techniques in the conscious patient as well as also easily during cardiosurgical interventions. New York
Heart Association severity degree of patients as well as physical activity improve in addition to (“on top” of) all
other therapeutic regimens. Stem cell therapy also represents an ultimate approach in advanced cardiac failure.
For acute myocardial infarction and chronic ischemia, long-term mortality after 1 and 5 years, respectively, is
significantly reduced. A few studies also indicate beneficial effects for chronic dilated cardiomyopathy. The clini-
cal use of autologous BMC therapy implies no ethical problems, when unmodified primary cells are used. With
the use of primary BMCs, there are no major stem cell-related side effects, especially no cardiac arrhythmias
and inflammation. Various mechanisms of the stem cell action in the human heart are discussed, for example,
cell transdifferentiation, cell fusion, activation of intrinsic cardiac stem cells, and cytokine-mediated effects. New
techniques allow point-of-care cell preparations, for example, within the cardiac intervention or operation the-
ater, thereby providing short preparation time, facilitated logistics of cell transport, and reasonable cost effec-
tiveness of the whole procedure. The 3 main indications are acute infarction, chronic ischemic heart failure, and
dilated cardiomyopathy. Future studies are desirable to further elucidate the mechanisms of stem cell action
and to extend the current use of intracoronary and/or intramyocardial stem cell therapy by larger and presum-
ably multicenter and randomized trials. (J Am Coll Cardiol 2011;58:1095–104) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.016Just over 10 years ago, on March 30, 2001, autologous
unfractionated mononuclear bone marrow stem cells
(BMCs) were used for the first time in the clinical treatment
of the failing left ventricle after acute myocardial infarction
in a 46-year-old patient by intracoronary application (1).
On July 3, 2001, the first intramyocardial application of a
purified (CD133) BMC preparation was applied to a
64-year-old patient with heart failure after myocardial
infarction during a coronary artery bypass graft (CABG)
operation starting a phase I trial (2). These early clinical
steps prompted a series of subsequent studies of acute and
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accepted April 7, 2011.chronic heart diseases, for example, in acute myocardial
infarction, in chronic cardiac failure, and in dilated cardio-
myopathy (DCM) (3–11). In the following overview, meth-
odological and clinical prerequisites of cardiac cell therapy
and cell preparation procedures are described, including the
experience with different cell application methods; it sum-
marizes recent results of currently available clinical studies
investigating the safety, feasibility, and efficacy of this new
kind of regenerative cell therapy in heart disease.
Remodeling
In acute myocardial infarction, heart muscle tissue is region-
ally destroyed. By the sum of CABG surgery and percuta-
neous coronary intervention (PCI), regular heart muscle
function may not be restored or only to a minor degree, so
that remodeling, which may occur in approximately 60% of
the patients after myocardial infarction, is mostly not
prevented (12–14). It is estimated that left ventricular
ejection fraction (LVEF) is improved after PCI by approx-
imately 3% to 4% only (15). Conversely, cell therapy—as a
causal treatment of myocardial hypoperfusion and cell
C
1
v
a
c
I
m
o
i
o
i
p
1096 Strauer and Steinhoff JACC Vol. 58, No. 11, 2011
10 Years of Cardiac Stem Cell Therapy September 6, 2011:1095–104loss—has the fundamental aim
to prevent remodeling by recon-
stitution of perfusion, thereby
leading to myocardial functional
recovery. That occurs preferably
in addition to (“on top” of) all
usual pharmacotherapeutic regi-
mens available for symptomatic
treatment of ischemic heart failure.
BMCs for Cardiac Repair
Various stem cell or progenitor
cell containing populations have
been introduced for cardiac re-
pair in the last few years, al-
though many past and ongoing
clinical trials use predominantly adult autologous BMCs
(16–18). The BMCs contain several cell populations that
have the capacity to proliferate, migrate, and also differen-
tiate into various mature cell types. Among these cells are
hematopoetic stem cells (19–32), mesenchymal stem cells
(33–40), endothelial progenitor cells (41–43), and side
population cells (44,45). In brief, human adult bone marrow
contains a variety of regenerative autologous precursor/
progenitor cells that enhance cardiac performance. The use
of BMC in cardiovascular diseases has the advantage that
bone marrow can be easily accessed, is renewable, and is an
autologous source for regenerative cells. The use of purified
and selective expanded cell populations may allow a more
specific cardiac stem cell therapy in the future.
Preparation of autologous BMCs for cardiac therapy.
Important prerequisites for clinical cell therapy are the
precise and careful preparation of the cells harvested from
the adult bone marrow, the concentration of high cell
numbers within the infarction, predominantly in the isch-
emic border zone, an enhanced migration of stem cells into
the apoptotic and necrotic myocardial tissue, and the hom-
ing of the injected cells in the damaged myocardium, to
avoid the recirculation loss of the injected cells to bone
marrow, spleen, liver, and lungs.
For cell therapy, 80 to 250 ml adult bone marrow blood
is aspirated from the iliac crest under local anesthesia. In the
past, the mononuclear fraction of cells was separated from
the whole bone marrow aspirate by density gradient centrif-
ugation using osmolaric media such as ficoll or gelatineoly-
succinate (3,4,46,47). However, both methods comprise
open preparation procedures and need several washing
steps; thus, both techniques need a good manufacturing
practice process to produce a quality-controlled cell product
and avoid contamination of the end product (48,49). That is
especially mandatory for further processing of CD133 or
CD34 purification of stem cells (2). Furthermore, both
manual preparation protocols take at least 4 h. During cell
preparation, viability needs to be determined several times,
Abbreviations
and Acronyms
BMC  bone marrow stem
cell
CABG  coronary artery
bypass graft
DCM  dilated
cardiomyopathy
LVEF  left ventricular
ejection fraction
PCI  percutaneous
coronary intervention
PTCA  percutaneous
transluminal coronary
angioplastyand finally must reach approximately 95%. Cell product icharacterization by fluorescence-activated cell sorting or a
cell counter is needed for individual release.
Recently, several new automatic systems were developed
to gain nucleated or mononuclear cells from the whole bone
marrow aspirate. The advantage of such systems is the
possibility to separate the cells in a closed system. In these
systems, the cell recovery is higher than with manual
preparation (50), and with the same functional capabilities
(51). Additionally, the preparation time is definitely shorter.
The cell preparation and cell application can be done in 1
working process, which is considerably cheaper than the
conventional BMC preparation procedures. Nowadays, 3
different separation strategies exist: 1) separation of the
total nucleated cells from the bone marrow aspirate (50);
2) separation of the mononuclear cell fraction (51); and
3) purification selection of specified stem cells including
CD34 or CD133 cells (52).
Most of these automatic separation systems separate
different cell populations. Therefore, the clinical specialist
has to decide which system fits best for the chosen appli-
cation and cardiovascular setting. Furthermore, a consensus
has to be reached to establish a standard protocol for
characterization and testing of transplantation products in
cardiovascular setting and a standard quality of the final cell
product.
Cell delivery to the heart. One of the most important and
crucial methodologic questions refers to the optimum mecha-
nism of cell delivery to the heart (53,54). When given intra-
venously, only a very small fraction of infused cells can reach
the infarct region; assuming normal coronary blood flow of 80
ml/min/100 g intravenous weight, a quantity of 160 ml per left
ventricle (assuming a regular ventricular mass of 200 g) will
flow per minute. This corresponds to approximately 3% of
cardiac output (assuming a cardiac output of 5,000 ml/min)
(55,56). Thus, intravenous application would require many
circulation passages to enable infused cells to come into contact
with the infarct-related artery. Throughout this long circula-
tion and recirculation time, homing of cells to other organs
could considerably reduce the number of cells dedicated to cell
repair in the area of interest, namely, in the infarcted zone.
Therefore, homing of stem cells to cardiac ischemic tissue from
the circulation, as shown by Ma et al. (57), has to be considered
a physiological process with restricted efficiency (58–63).
linical evaluation of homing to infarcted myocardium with
8-fluorodeoxyglucose labeling of unselected BMC has re-
ealed a cardiac retention of 1.3% to 2.6% after intracoronary
pplication (58). The current principles of clinically employed
ell delivery methods are depicted in Figure 1 (64).
ntracoronary application. Supplying the entire heart
uscle compartment by intracoronary cell administration
bviously seems to be advantageous for tissue repair of
nfarcted heart muscle after interventional reopening of the
ccluded coronary artery. Cells are able to flow through the
nfarcted and peri-infarct tissue during the immediate first
assage of the post-ischemic region. Accordingly, by this
ntracoronary procedure the infarct tissue and the peri-
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circulation access of the tissue compartments.
A selective intracoronary delivery route, therefore, has
been developed clinically (1) that minimizes the cell loss
due to extraction toward organs of secondary interest by
this first-pass–like effect. To facilitate transendothelial
passage and migration into the infarct zone, cells are
infused by pressure injection directly into the perinecrotic
tissue accompanied by ischemic pre-conditioning. This is
accomplished by a balloon catheter-induced ischemia,
which is placed within the infarct-related artery. After
exact positioning at the site of the former infarct vessel
occlusion, percutaneous transluminal coronary angio-
plasty (PTCA) is performed. During this time of vessel
occlusion, cells are infused intracoronarily through the
balloon catheter, using 4 fractional high-pressure infu-
sions of 5 ml cell suspension, each of which contains 6 to
10 million mononuclear cells. The PTCA thoroughly
prevents backflow of cells and at the same time produces
a stop flow beyond the site of balloon inflation to
facilitate migration of cells into the infarcted zone. Thus,
prolonged contact time for cellular migration is allowed,
and cells are not washed away immediately under these
conditions. This migration process is probably only
present in injured and ischemic tissue (59). The induc-
tion of stem cell specific adhesion molecules in the late
phase after ischemia-reperfusion injury seems to be the
crucial step for stem cell homing and is relevant for the
timing of stem cell therapy (59).
Endocardial intramyocardial application. A second inter-
ventional delivery route for cardiac stem cell transplantation
is the transendocardial catheter injection (58), preferably
using the NOGA injection catheter (Biosense Webster
Ltd., Diamond Bar, California), which is placed across the
Figure 1 Various Transplantation Methods in Heart Disease
(A) Intracoronary and (B) intramyocardial transplantation methods in heart diseas
in cardiac intervention and cardiac surgery. CFX  circumflex artery; LAD  left anaortic valve into the target area (65,66). This interven-tional approach offers intramyocardial cell delivery simi-
lar to the surgical approach with being less invasive at the
same time. The first clinical studies were able to prove
safety and feasibility of the transendocardial route in the
setting of chronic ischemic heart disease (65) as well as
for intractable angina (66). However, orientation by
electromechanical mapping is technically demanding,
and cell loss into the ventricle, wrong injections sites,
ventricular arrhythmias, and cardiac tamponade can
occur.
Epicardial intramyocardial application. Surgical (epicar-
dial) stem cell application is performed into well-exposed
ischemic areas, allowing for multiple injections within and
principally around the infarct area with a thin needle. First
clinical studies performed stem cell injection in combination
with CABG (2). Once the graft–coronary artery anastomo-
sis is completed, the ischemic area is visualized, and the cells
are injected into the border zone of the infarcted area
(2,9,67).
This method has been applied successfully also during
off-pump coronary artery bypass grafting as well as a
stand-alone minimally invasive procedure in which cell
injection is performed without cardiac arrest. As with the
transendocardial cell delivery, intramyocardial stem cell
injection during surgery seems to overcome the problem
linked to insufficient vascularization, migration, and homing
of transplanted stem cells more likely than to the attempts
to influence stem cell migration process in the vasculature
and results in a high stem cell persistence in heart muscle
(67). Recent reports about surgical stand-alone stem cell
therapy are of great interest (60,68,69). Therein, patients
improved in myocardial perfusion and clinical symptoms as
a result of stem cell injection only through lateral minitho-
racotomy. Besides distinguishing between stem cell and
icted are clinically used methods for vascular and myocardial cell delivery
descending artery; LV  left ventricle; RCA  right coronary artery.e. Dep
teriorrevascularization effects on cardiac function, this approach
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context of surgical stem cell therapy.
Mechanisms of stem cell action in the diseased heart.
The regenerative potential of bone marrow-derived stem
cells may be explained by at least any of 4 mechanisms:
1) direct cell transdifferentiation from BMCs to cardiac
myocytes (19,70); 2) cytokine-induced myocyte growth
(18,23) and increase of residual viable myocytes (especially
in the border zone of the infarcted area); 3) stimulation of
intrinsic myocardial stem cells (endogenous stem cells) (18);
and 4) induction of cell fusion between transplanted BMCs
and resident myocytes (71,72), which was taken as an
explanation for transdifferentiation.
The influence of cytokines has been shown to restore
coronary blood vessels and muscle cells after experimental
infarction by angiogenesis. Bone marrow stem cells express
a bounty of cytokines (e.g., vascular endothelial growth
factors, insulin-like growth factor, platelet-derived growth
factor), thereby stimulating residual normal myocytes for
regeneration (31,71,73) and proliferation, and intrinsic
myocardial stem cells (endogenous stem cells) for cell
regeneration and fusion.
The importance of ischemic pre-conditioning. Stromal-
derived factor-1 and its receptor CXCR4 are well estab-
lished to be essential for the enhancement of hematopoetic
progenitor cell recruitment and angiogenesis (60–63). The
expression of stromal-derived factor-1 is up-regulated dur-
ing acute ischemia and stimulates the CXCR4 receptor,
which is expressed on endothelial progenitor cells and
BMCs, thereby acting as a chemotactic and promigratory
factor. Currently, it is not known how many cells are exactly
retained in the myocardium after intracoronary infusion and
migrate into the border zone. Because myocardial ischemia
may be an appropriate stimulus for a stem cell to find its
optimum myocardial niche, the ischemia-producing stimu-
lus, for example, by balloon dilation during the BMC
infusion (ischemic pre-conditioning), seems to be important
for the cells to home into the cardiac endothelium
(49,57,74). It is obvious that cells may pass through the
coronary vascular bed without significantly enhanced hom-
ing to coronary endothelium when only injected into the
coronary arteries without pre-conditioning interventions.
With respect to obvious differences in the intracoronary
delivery techniques used in various publications, the variable
outcome of results and therapeutic efficiency may be due to
the nonstandardized mode of BMC infusion into the
coronary circulation. Precise methodological standardiza-
tion seems to be relevant for both effectiveness of stem cell
therapy in clinical heart disease and the comparability of
multicenter stem cell studies (49,57,74).
Cell therapy in the elderly cardiac patient. With aging,
there is an increase in the incidence and severity of ischemic
cardiovascular diseases. Pharmacotherapeutical regimen as
well as revascularization therapy, such as PTCA or CABG,
are not sufficient to bring about an improvement of a widely
impaired cardiac function. However, it has been suggestedthat therapeutic stem cell application may offer hope for
these severely ill patients (75), although some data suggest
that cell therapy may have only a limited effect in the elderly,
because of the physiological changes that have occurred in
the aged myocardium, and by the aged (autologous) stem
cells themselves.
For elderly patients who remain symptomatic despite
intensive medical treatment, autologous BMCs represent a
very promising attempt to repopulate lost myocardial tissue.
To intensify the benefit of the autologous stem cell appli-
cation in the elderly: 1) an increased extraction of bone
marrow blood and cell number; 2) a pre-treatment of the
bone marrow-derived mononuclear cells with specific
growth factors in vitro; 3) the injection of a higher amount
of regenerative cells; and 4) enhanced ischemia of the
myocardium induced by prolonged intracoronary balloon
dilation will all have to be considered for treatment im-
provement in the future. Therapy with BMCs is ethically
justified for treatment of patients of all ages.
Clinical Results and Indications
Acute myocardial infarction. In acute myocardial infarc-
tion, a variety of studies have demonstrated longstanding (up to
3 years and more) improvement of ventricular performance
after using stem cell therapy, resulting in an increase in ejection
fraction by 3% to 36% (mean 11.4%) and decreased infarct
size by 1% to 60% (mean 34%) (Table 1) (1,3–5,32,76). In
most studies, stem cell transplantation was performed in a
time frame of 8 to 14 days after infarction. Although large
variability of hemodynamic data after cell therapy exists
(Table 1), there is moderate, but unequivocal improvement
of performance of the infarcted heart after stem cell therapy
that is quantitatively more than the sum of the interven-
tional measures (PTCA, stent) and may be achieved in
addition to these therapeutic interventions and to pharma-
cotherapy (4,46). Thus, autologous stem cell therapy repre-
sents an innovative and effective procedure for regeneration
of impaired heart muscle in the early phase after the infarct
(3–5,32,46,77–88).
The reason for the large variety of stem cell effects and for
minor or negative results in some studies may be stem
cell-related or dependent on different methods for the
heart’s functional evaluation: for example, by: 1) different
methodology of cell preparations associated with altered cell
viability; 2) various ages of patients with age-dependent loss
of cell viability; 3) nonstandardized cell delivery to the heart,
especially of the intensity of ischemic pre-conditioning
during cell transfer, which represents an important prereq-
uisite for ischemia-induced cell migration; 4) various
amount of delivered cells; 5) different times between the
acute infarct and stem cell therapy; and 6) noncalculable
access to the border zone between the infarct and unaffected
tissue because of vessel occlusion or nonsufficient intracoro-
nary cell delivery. Moreover, methods for the assessment of
ventricular function and perfusion (ventriculography, echo-
v m cells
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emission computed tomography) are often not comparably
used. This variability of methods probably may lead to
nonuniform and nonstandardized cell availability to the
damaged area of interest and may impede the comparability
of data of various trials. Therefore, exact and comparable
methodology of cell preparation, of cell delivery, and of the
clinical patient selection and procedures are necessary.
Chronic infarction/ischemic heart disease. To date, sev-
eral clinical studies have revealed beneficial stem cell effects
Landmark Trials of Intracoronary and Intramyocardial Stem Cell ThTable 1 Landmark Trials of Intracoronary and Intramyocardial S
First Author/Study
(Ref. #)
(Type of Study) n
Cell Application
After AMI
Stem Cell Therapy in A
Strauer 2001 (1) (C) 1 6 days
Strauer 2002 (3) (C) 20 7–9 days
1:1 vs. control
TOPCARE-AMI (4) (C) 59 4–6 days
Chen (97) (C) 69 18 days
1:1 vs. control
BOOST (5) (R) 60 4–6 days
1:1 rand.
Janssens (6) (R) 67 24 h
1:1 rand. placebo, double-blind
BALANCE (32) (R) 124 7 days
TACT-PB-AMI (83) (R) 54 3 days
Cardiac Study (84) (R) 38 4 days
REGENT (85) (R) 200 3–12 days
BONAMI (87) (R) 100 7–10 days
ASTAMI (89) (R) 100 6 days
1:1 rand.
REPAIR-AMI (46) (R) 204 4 days
1:1 rand. placebo, double-blind
Chronic Ische
Strauer (7) (C) 36 3 months to
1:1 vs. controls 9 yrs
TOPCARE-CHD (89) (R) 75 3 months
BMC group
Circ. prog. group
Control group
STAR (97) (C) 391 8.5 3.2 yrs
The percent changes (/) refer to the percent change of parameter before and after cell therap
BMC  bone marrow stem cell; C  controlled study; Circ. prog.  circulating progenitor cells; E
entricular; M  meta-analysis; MRI  magnetic resonance imaging; MSC  mesenchymal ste
ingle-positron emission computed tomography.in subacute and chronic ischemic heart failure (Table 1).Surgical studies have also been designed for this setting
(Table 2) (90–92). Combined with CABG, the improve-
ment of cardiac function by the use of BMCs has been
described as an increase in LVEF of approximately 10%
(2,67,93,94). Studies combining stem cell transplantation
with off-pump coronary surgery report similar results (95),
implicating that cardiac arrest is not mandatory for safe and
efficient stem cell implantation. However, these results will
always be difficult to interpret conclusively without consid-
eration of revascularization effects. Therefore, recent reports
in Acute and Chronic Ischemic Heart DiseaseCell Therapy in Acute and Chronic Ischemic Heart Disease
cation Cell Type Number of Cells Results Method
Myocardial Infarction
12 106 EF 16% GBP
Cardiac index 30% GBP
Infarct size 36% SPECT
28 106 EF 9% LV angiogram
Infarct size 60% LV angiogram
rog. 16 106 EF 16% LV angiogram
213 106 ESV 25% LV angiogram
om bone marrow EF 36% LV angiogram
ESV 53% LV angiogram
Infarct size 60%
s. rand. controls 2,460 106 EF 13% MRI
ESV 2% MRI
Infarct size 43% MRI
s. i.c. placebo 304 106 EF 7% MRI
ESV 3% MRI
Infarct size 50% MRI
s. rand. controls 6.1 107 EF 4.6% LV angiogram
ESV 3.6 ml LV angiogram
Infarct size 8.2% LV angiogram
5 109 EF 13% LV angiogram
s. rand. controls 41.8 107 EF 13.1% SPECT
178 106 EF 3% MRI
CXCR4 1.9 106 EF 3% MRI
s. rand. controls 98 106 BMC, EF 4.3% SPECT
Controls, EF 3.3% SPECT
s. rand. controls 87 106 EF 1.9% SPECT
Infarct size 25% SPECT
s. i.c. placebo 230 106 EF 11% LV angiogram
ESV 1% LV angiogram
eart Disease
28 106 EF 15% LV angiogram
Infarct size 30% LV angiogram
205 106 EF 7% (BMC) LV angiogram
rog. 22 106 ESV, infarct size 4% LV angiogram
sion LV angiogram
6.6 107 EF 6.7% LV angiogram
ESV 18 ml LV angiogram
Infarct size 4.5 LV angiogram
ction fraction; ESV  end-systolic volume; GBP  gated blood pool; i.c.  intracoronary; LV  left
; PBSC  peripheral blood stem cell(s); R  randomized study; rand.  randomized; SPECT erapytem
Appli
cute
BMC
BMC
Circ. P
BMC
MSC fr
BMC v
BMC v
BMC v
PBSC
BMC v
BMC
CD34
BMC v
BMC v
BMC v
mic H
BMC
BMC
Circ. p
No infu
BMC
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study reported not only a gain in cardiac function but also a
clear improvement in quality of life for patients with chronic
ischemic heart disease and refractory angina treated after
stand-alone bone marrow stem cell injection through lateral
minithoracotomy (69).
Interventional studies using intracoronary or endocardial
stem cell application have also been performed in the setting
of chronic ischemic heart failure. These studies report an
improvement of LVEF to a similar extent as in surgical
trials. Furthermore, a significant decrease in infarction size
and an improved overall myocardial oxygen uptake have
been described (6,96). The largest study, STAR (acute and
long-term effects of intracoronary Stem cell Transplantation
in 191 patients with chronic heARt failure) heart study,
included 391 patients with chronic heart failure (New York
Heart Association functional class 3.22 and 3.06, respec-
tively; LVEF 35%) (97). Within the wide range of 3
onths to 5 years after intracoronary BMC therapy, there
as significant improvement in hemodynamics (e.g.,
VEF, cardiac index), exercise capacity, oxygen uptake, and
eft ventricular contractility. Importantly, there was a sig-
ificant decrease in the long-term mortality of treated
atients in comparison to the control group (Fig. 2) (97).
hus, intracoronary BMC therapy improves ventricular
erformance, quality of life, and survival in patients with
hronic heart failure.
ilated cardiomyopathy. In the last years, few data have
Landmark Trials of Epicardial Intramyocardial Stem Cell Therapy inTable 2 Landmark Trials of Epicardial Intramyocardial Stem Ce
First Author/Study
(Ref. #)
(Type of Study) n
Cell Application
After AMI Application Cell Type
Stem Cell Therapy i
Stamm (9) (R) 40 Median 9 weeks CD133 BMC
vs. CABG alone
Patel (95) (C) 20 n.a. CD34 BMC
vs. CABG alone
Hendrikx (108) (R) 20 31.0 23.2 weeks BMC-MN 6
vs. CABG alone
Ahmadi (93) (C) 27 10.5 0.2 weeks CD133 BMC
vs. CABG alone
Meta-Analyses of Stem Cell Th
Hristov (90) (M) 241  7 days BMC 2
Lipinski (8) (M) 698 5 days BMC, pred.
Abdel-Latif (91) (M) 999 10 days BMC, pred.
Burt (92) (M) 1,002 BMC, pred.
CABG  coronary artery bypass graft surgery; EDV  end-diastolic volume; LVA  left ventricular a
bbreviations as in Table 1.een reported on stem cell therapy for dilated cardiomyop-thy (DCM) (96,98). This first-in-human study of autolo-
ous bone marrow cells in DCM, ABCD (Autologous
one marrow Cell trial in Dilated cardiomyopathy), inves-
igated 44 patients, and the Düsseldorfer ABCD trial
nvestigated 20 patients (96,98). In both studies, none of the
atients had coronary disease (excluded by angiography) or
yocarditis (excluded by endomyocardial biopsy). In both
rials, cell transplantation was performed by the intracoro-
ary administration route in either coronary artery.
emic Heart Diseaserapy in Ischemic Heart Disease
ber of Cells Results Method
emic Heart Disease
.8 106 EF 9.7 8.8% (BMC) Echocardiography
EDV 11.1 38.6 (BMC)
2 106 EF 16.7 3.2% (BMC) Echocardiography
EDV 22.0 27.6 (BMC)
31.35 106 EF  6.1 8.6% (BMC-MN) MRI
0.03 106 EF 3.7 6.3% (BMC) Echocardiography
in Acute Myocardial Infarction
106 EF 4% LVA p  0.04
106 EF 3% LVA, SPECT, MRI p  0.001
Infarct size 6% LVA, SPECT, MRI p  0.001
ESV 7 ml LVA, SPECT, MRI p  0.002
EDV 5 ml LVA, SPECT, MRI NS
106 EF 4% LVA, SPECT, MRI p  0.001
Infarct size 7% LVA, SPECT, MRI p  0.003
ESV 6 ml LVA, SPECT, MRI p  0.006
EDV 3 ml LVA, SPECT, MRI NS
n.a. EF 2% to 5% Echocardiography,
MRI
NS
phy; MN mononuclear; n.a.  not available; NS  not significant; pred.  predominantly; other
Figure 2 Effect of BMC Therapy on Survival
Effect of bone marrow cell (BMC) therapy (green line) on survival of patients
with chronic ischemic cardiomyopathy (97). Blue line indicates control group.Ischll The
Num
n Isch
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Association functional classification. Ejection fraction im-
proved by 5.4% to 8%. Physical ability (functional capacity)
rose from 25 to 75 W. Furthermore, reduction of arrhyth-
mias was documented. Both trials found reduction in
end-systolic volumes and no change in end-diastolic vol-
umes. These first results show that transplantation of
autologous bone marrow cells as well as the intracoronary
approach represent a potential effective therapeutic proce-
dure for DCM.
Indications for cell therapy. The therapeutic extract re-
sulting from the 16 largest controlled and randomized
studies (n  1,598) (Table 1) shows for acute myocardial
infarction and for chronic ischemic heart failure an improve-
ment of LVEF by a mean 11.3%. Considering the 4
meta-analyses involving 2,940 patients, the increase in
ejection fraction (mean 4%) is much lower, but still signif-
icant. This hemodynamic pattern is compatible with the
symptomatic improvement (New York Heart Association
functional class, exercise tolerance) and with reduced mor-
tality in treated patients (Fig. 2).
The best tested indications for BMC therapy are a
previous myocardial infarction with large infarct area, an-
eurysm, and depressed ejection fraction, as well as heart
failure due to chronic ischemic heart disease (99). The age
of the infarct seems to be less relevant for the regenerative
potency of BMCs, because this therapy for old infarcts (8
years) is almost equally effective as it is for recent infarcts (8
to 14 days). This regenerative phenomenon is probably
related to a persistence of the border zone, which is also
present in chronic infarcts. Positive results that have also
been reported for DCM with severely depressed ejection
fraction encourage further studies in advanced heart failure
due to heart muscle diseases.
Taking all this into account, it may be concluded that cell
transplantation within the first 5 days after acute infarction
is not possible for logistical reasons of the critically ill
patient and is not advisable because of the inflammatory
process (100–102). Although the ideal time point for
transplantation remains to be defined, it is most likely
between days 7 and 14 after the onset of myocardial
infarction.
Clinical Safety
The procedure of intracoronary autologous bone marrow
cell transplantation in patients with acute myocardial infarc-
tion, chronic coronary artery disease, and nonischemic
DCM is effective and safe. No increase of malignant
diseases or inadequate progression of coronary artery dis-
eases has been documented (91). To assess any inflamma-
tory response and myocardial reaction after intracoronary
autologous stem cell transplantation, white blood cell count,
serum levels of C-reactive protein and of creatine phospho-
kinase are measured before, during, and after treatment, and
these data collected revealed no evidence of inflammation. NNeither procedural or cell-induced complications nor any
other type of side effects have occurred so far.
Ongoing Clinical Trials
Several trials running currently are trying to answer the
questions mentioned in the preceding text. Regarding the
effect of intracoronary bone marrow progenitor cell infusion
in the setting of acute myocardial infarction, placebo-
controlled Phase II/III trials like REGEN-AMI (Bone
Marrow Derived Adult Stem Cells for Acute Anterior
Myocardial Infarction) are of interest. In the field of surgical
cell therapy, the recently launched PERFECT (intramyo-
cardial transPlantation of bonE maRrow stem cells For
improvEment of post-inFarct myoCardial regeneraTion in
addition to CABG surgery) study is the first placebo-
controlled, double-blinded, multicenter Phase III trial in-
vestigating the effects of intramyocardial BMC injection
combined with CABG surgery. Although representing
Phase I and II levels, PROMETHEUS (Prospective Ran-
domized Study of Mesenchymal Stem Cell Therapy in
Patients Undergoing Cardiac Surgery) is highly interesting
because it represents the first-in-human study analyzing the
safety and efficacy of intramyocardial injection of mesenchy-
mal stem cells during CABG in patients scheduled for
coronary surgery due to ischemic heart disease, as an
alternative cell population to the hematopoietic progenitor
cell populations mainly used in clinical trials for cardiac
regeneration so far. In this respect, the combination treat-
ment of purified endothelial progenitor cells and mesenchy-
mal stem cells has been addressed successfully in a Phase I
trial with intramyocardial injection (103). There are several
more interesting trials currently recruiting patients, and
results from all of these are needed for a valid evaluation of
the gain in cardiac function related to stem cell therapy.
Dose-dependent contribution for cardiac recovery. Iwa-
saki et al. (104) found dose-dependent augmentation of
cardiomyogenesis and vasculogenesis after transplanta-
tion of human CD34 cells into rat infarcted myocar-
ium. Enhanced capillary density, inhibition of left
entricular fibrosis, and increased recovery of the left
entricular function was associated with higher numbers
f transplanted CD34 cells. These findings suggest that
se of higher doses of CD34 cells may be more potent
for therapeutic application to the damaged myocardium
than a lower dose. In their study, they also found that
there was no beneficial effect of CD34 cells in their
ow-dose group (1103 cells/kg) (104). Recently, clinical
ata also showed the dose-dependency influence of
D34 cells on left ventricular function and perfusion
105).
thical considerations. The use of human autologous
MCs containing (progenitor) stem cells for cardiac regen-
rative therapies can be clinically justified and is ethically
nquestionable as long as unmodified primary cells are used.
o major side effects have been reported so far, especially
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differentiation of embryonic stem cells to contractile heart
cells, there is no arrhythmogenic potential of BMCs, and
immunosuppressive therapy is unnecessary. Thus, the ther-
apeutic advantage clearly prevails, and clinical use has
already been realized.
Perspectives
Future studies should aim at defining the optimum tech-
nique of cell preparation, discovering the best cell type and
amount for myocardial regeneration, analyzing their hom-
ing characteristics to the cardiac endothelium and to extra-
cardiac organs, improving cell delivery techniques, and
trying to establish indications for cell therapy in various
heart diseases (62). Joint and cooperative studies between
pre-clinical and clinical research are essential. The mecha-
nisms of stem cell-related cardiac repair need to be further
investigated and alternative modes of action such as para-
crine activity and immunomodulation should be considered.
Furthermore, attempts to create dynamic “multi-lineage”
cardiac regeneration by combining cell therapy with tissue-
engineered scaffolds or cardiac resynchronization therapy
(106–108) should be further supported because they offer a
realistic perspective to come to an integrated regenerative
approach.
As with each new therapy, new questions arise parallel to
its clinical use: the following methodologic and therapeutic
questions would be worth to be analyzed in the future: 1) to
define the optimum technique of cell preparation; 2) to
standardize cell separation procedures; 3) to evaluate the
quality of the cell end product; 4) to discover the best cell
type for myocardial regeneration; 5) to analyze cell homing
characteristics to the cardiac niche; 6) to characterize the
mode of action of stem cells for cardiac regeneration; 7) to
improve cell delivery techniques; and 8) to label stem cells
for determining stem cell fate. Interest should be focused on
adult stem cell projects that have already proven significant
clinical efficacy, but without having any ethical concerns.
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